United States· US:59651-601_dc2886e0-4e19-4a7c-b7ae-5723d7b4b8c9
Deflazacort
A deflazacort product containing deflazacort, registered in United States by Aurobindo Pharma Limited. The same ATC class is registered in 8 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Deflazacort is registered in 8 of 19 countries.
Countries holding a registration under ATC H02AB13 (deflazacort), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 3 of them publish a price we can compare per daily dose
Deflazacort · ATC H02AB13
8 / 19 countries
- Denmark
- Finlandprice
- Germany
- Netherlands
- Norwayprice
- Sweden
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of deflazacort costs, country by country.
Normalised to the WHO defined daily dose (15 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Deflazacort · price per daily dose (15 mg)
USD · FX 28 Sept 2026
- ES Spain$0.19
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- Deflazacort
- Manufacturer
- Aurobindo Pharma Limited
- Country
- United States (US)
- ATC code
- H02AB13
- ATC class
- Deflazacort
- Defined daily dose
- 15 mg, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- June 3, 2026
Packs & prices · 1
- ndc11596516013030 TABLET in 1 BOTTLE (59651-601-30)
Regulatory notes
Interactions
434 interactions on record for deflazacort.
Graded by severity as the source publishes them — 129 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Deflazacort · interactions on record
434 records
- 129 severe
- 297 moderate
- 8 minor
Most severe, free to view
- AprepitantA04AD12severe
- LonafarnibA16AX20severe
- DesirudinB01AE01severe
- BerotralstatB06AC06severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Deflazacort in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainDEFAL 30 MG COMPRIMIDOS EFGFaes Farma S.A.
- FinlandDeflazacort XGX PharmaXGX Pharma ApS
- United KingdomCalcort 30mg tabletsShire Pharmaceuticals Ltd
- NetherlandsDeflazacort XGX Pharma 30 mg tablettenXGX Pharma ApS
- SwedenDeflazacort XGX Pharma 30 mg TablettXGX Pharma ApS
- NorwayCalcortGalen Pharma GmbH
- GermanyCalcortGalenpharma Gmbh
Authorised across Europe · EMA
The same active substance is authorised in 10 EEA countries. Names it is sold under:
- Germany · Calcort, Deflazacort Galen
- Denmark · Deflazacort Vital Pharma Nordic
- Spain · Defal, Deflazacort Cinfa
- Finland · Deflazacort Vital Pharma Nordic
- United Kingdom (Northern Ireland) · Calcort
- Italy · Decor, Deflan
- Netherlands · Deflazacort Xgx Pharma
- Norway · Deflazacort Xgx Pharma
- Portugal · Deflazacorte Acizan, Deflazacorte Almus
- Sweden · Deflazacort
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d9b39b76-bcfe-4bd3-8c77-6b0b79335102 GET /v1/drugs/d9b39b76-bcfe-4bd3-8c77-6b0b79335102?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unii": {
"unii": "KR5YZ6AE4B",
"rxcui": "22396",
"inchikey": "FBHSPRKOSMHSIF-GRMWVWQJSA-N",
"display_name": "DEFLAZACORT",
"substance_type": "chemical",
"ingredient_type": "INGREDIENT SUBSTANCE"
},
"route": "ORAL",
"spl_meta": {
"2fac1332-0247-1047-e063-6294a90a557f": {
"match": "brand_token",
"title": "DEFLAZACORT ORAL SUSPENSION (DEFLAZACORT ORAL) SUSPENSION [SUN PHARMACEUTICAL INDUSTRIES, INC.]",
"spl_version": "2",
"published_date": "2026-02-02"
}
},
"productid": "59651-601_dc2886e0-4e19-4a7c-b7ae-5723d7b4b8c9",
"productndc": "59651-601",
"dosage_form": "TABLET",
"orange_book": {
"appl_no": "217123",
"products": [
{
"rs": false,
"rld": false,
"te_code": "AB",
"strength": "6MG",
"product_no": "001",
"approval_date": "Feb 9, 2024"
},
{
"rs": false,
"rld": false,
"te_code": "AB",
"strength": "18MG",
"product_no": "002",
"approval_date": "Feb 9, 2024"
},
{
"rs": false,
"rld": false,
"te_code": "AB",
"strength": "30MG",
"product_no": "003",
"approval_date": "Feb 9, 2024"
},
{
"rs": false,
"rld": false,
"te_code": "AB",
"strength": "36MG",
"product_no": "004",
"approval_date": "Feb 9, 2024"
}
],
"appl_type": "A"
},
"dea_schedule": null,
"product_type": "HUMAN PRESCRIPTION DRUG",
"substance_name": "DEFLAZACORT",
"proprietary_name": "Deflazacort",
"active_ingred_unit": "mg/1",
"application_number": "ANDA217123",
"marketing_category": "ANDA",
"nonproprietary_name": "Deflazacort",
"start_marketing_date": "20240209",
"active_numerator_strength": "30"
}See everything about deflazacort.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.